Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas

PLUS THERAPEUTICS, INC.

2025-Q2 EPS reported -$0.50 revenue$2,449,000

Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.
CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.
REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.
Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.